- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment | 195 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillment... ► Artikel lesen | |
| 26.04. | Sagaliam Acquisition Signs Novation Agreement with Enzolytics | 1 | The SPAC Conference | ||
| 26.04. | Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc. | 360 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC... ► Artikel lesen | |
| 23.04. | Enzolytics, Inc.: Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada | 223 | ACCESSWIRE | Offers Update on OTC Annual Report and Business Model ALLEN, TX / ACCESSWIRE / April 23, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com)(the "Company") today disclosed that on April 9, 2024... ► Artikel lesen | |
| 12.04. | Enzolytics, Inc.: Update on Formulation of New Business Strategy | 244 | ACCESSWIRE | INFORMATION ON ENZOLYTICS, INC.BOARD OF DIRECTORS AND CHIEF EXECUTIVE OFFICERUPDATE ON FORMULATION OF NEW BUSINESS STRATEGYALLEN, TX / ACCESSWIRE / April 12, 2024 / Enzolytics, Inc. (OTC PINK:ENZC)... ► Artikel lesen | |
| 20.11.23 | Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure | 295 | ACCESSWIRE | Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/"https://enzolytics.com/).... ► Artikel lesen | |
| 18.09.23 | Enzolytics, Inc.: Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp | 1.672 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com).Enzolytics, Inc. announces today that it has executed the binding business combination... ► Artikel lesen | |
| 06.09.23 | Enzolytics, Inc.: Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency | 514 | ACCESSWIRE | Start date is expected by the end of 2023 / beginning of 2024. VIRO also offers an update on Diabetic trials and Sagaliam transaction.ALLEN, TX / ACCESSWIRE / September 6, 2023 / Enzolytics, Inc. (OTC... ► Artikel lesen | |
| 05.09.23 | Enzolytics, Inc.: Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention. | 466 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / September 5, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company"... ► Artikel lesen | |
| 24.08.23 | Enzolytics, Inc.: Biogenysis' International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application. | 460 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation... ► Artikel lesen | |
| 08.08.23 | Enzolytics, Inc.: Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment | 449 | ACCESSWIRE | Reports on Business combination agreement progressALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc. ("VIRO") a wholly owned subsidiary... ► Artikel lesen | |
| 04.08.23 | Enzolytics, Inc.: Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes | 494 | ACCESSWIRE | Progress on Sagaliam Acquisition Corp TransactionALLEN, TX / ACCESSWIRE / August 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc. ("VIRO"), a wholly owned subsidiary... ► Artikel lesen | |
| 24.07.23 | Enzolytics, Inc.: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC | 1.511 | ACCESSWIRE | p>ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). CORRECTEDVirogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company"... ► Artikel lesen | |
| 21.07.23 | Enzolytics, Inc.: Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease. | 399 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / July 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company"... ► Artikel lesen | |
| 11.07.23 | Enzolytics, Inc.: Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp. | 869 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. ("ENZC" or the "Company") filed a Supplemental Information report today... ► Artikel lesen | |
| 06.07.23 | Enzolytics, Inc.: Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials | 1.175 | ACCESSWIRE | ALLEN, TX / ACCESSWIRE / July 6, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC")... ► Artikel lesen | |
| 30.06.23 | Sagaliam Acquisition Corp. Announces Amendment to Non-Binding Term Sheet with Enzolytics Inc. and Addition of New Board Members | 494 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / June 30, 2023 / Sagaliam Acquisition Corp. (NASDAQ:"SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it has amended the executed non-binding... ► Artikel lesen | |
| 29.06.23 | Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. | 464 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / June 29, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam... ► Artikel lesen | |
| 26.06.23 | Enzolytics, Inc.: Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project | 468 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / June 26, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, today provided... ► Artikel lesen | |
| 05.06.23 | Enzolytics, Inc.: Enzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency Permitting and Arican ITV-1 Project | 408 | ACCESSWIRE | COLLEGE STATION, TX / ACCESSWIRE / June 5, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, today provided... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,540 | -0,68 % | Evotec, Vidac Pharma, BioNTech - das Milliardenrennen um die Krebstherapie | Die Onkologie steht an der Schwelle zu einer goldenen Ära. Getrieben von einer Zunahme der Krebserkrankungen und beeindruckenden wissenschaftlichen Fortschritten, darunter Gen- und Immuntherapien, eröffnet... ► Artikel lesen | |
| QIAGEN | 39,820 | +0,49 % | Qiagen schwächelt - Aktie rutscht ab | Im ersten Quartal 2024 verzeichnete der Labordienstleister und Diagnostikspezialist Qiagen schwächelnde Ergebnisse. Die andauernde Nachfrageflaute drückte auf Umsatz und Ergebnis. Das belastet die Aktie... ► Artikel lesen | |
| CG ONCOLOGY | 33,950 | -3,28 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| KEROS THERAPEUTICS | 58,68 | 0,00 % | Keros Therapeutics files automatic mixed shelf | ||
| VERA THERAPEUTICS | 44,970 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| BIONTECH | 85,20 | -0,23 % | Cracking The Code: Understanding Analyst Reviews For BioNTech | ||
| SUMMIT THERAPEUTICS | 5,310 | 0,00 % | Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 21,230 | +4,43 % | Edgewise Therapeutics, Inc. - 8-K, Current Report | ||
| MORPHOSYS | 66,80 | -0,15 % | MorphoSys: Effekte der Novartis-Übernahmeofferte sorgen für hohen Quartalsverlust | Übernahmekandidat MorphoSys schließt das erste Quartal 2024 mit einem Verlust im fortgeführten Geschäft von 311 Millionen Euro ab nach 32,2 Millionen Euro Minus im Vorjahresquartal. Der Umsatz steigt... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,650 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 38,440 | +0,34 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 17,080 | +2,89 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate Progress | OJEMDA (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,795 | 0,00 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| ARCELLX | 52,42 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| JANUX THERAPEUTICS | 61,47 | 0,00 % | Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen |
ENZOLYTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
